Granted Patent B2

US 12,638,445 · App. 18/243,540 · Granted May 26, 2026

Inventors: Gregory J. Bullington (Seattle, WA); Jay M. Miazga (Langley, WA); Shan E. Gaw (Seattle, WA); Paul E. Goldenbaum (San Antonio, TX); Dylan Guelig (Seattle, WA)

Assignee: Magnolia Medical Technologies, Inc.

G01N33/54388B01L3/0217B01L3/502715G01N33/5304B01L2300/0819B01L2400/0403

Abstract

Claims (13)

1 . A system, comprising:

a fluid transfer device, the fluid transfer device including a housing forming an inlet configured to be placed in fluid communication with a bodily fluid source and an outlet configured to be placed in fluid communication with a sample reservoir,

the housing including a sequestration chamber and a port in fluid communication with the sequestration chamber, the sequestration chamber configured to be placed in fluid communication with the inlet via a first flow path to receive a first volume of bodily fluid when the fluid transfer device is in a first state, the outlet configured to be placed in fluid communication with the inlet via a second flow path to receive a second volume of bodily fluid when the fluid transfer device is in a second state; and

a flow-based assay device disposed in the housing between the inlet and the outlet, the flow-based assay device coupled to the port to receive a portion of the first volume of bodily fluid via a third flow path when the fluid transfer device is in a third state, the flow-based assay device configured to provide an indication associated with the presence of a target analyte in the portion of the first volume of bodily fluid.

2 . The system of claim 1 , wherein the third flow path is different from each of the first flow path and the second flow path.

3 . The system of claim 1 , wherein the first volume of bodily fluid is sequestered from the first flow path when the fluid transfer device is in the second state.

4 . The system of claim 3 , wherein the second volume of bodily fluid flows through the second flow path, thereby bypassing the sequestration chamber and the first volume of bodily fluid sequestered therein.

5 . The system of claim 1 , wherein the port is configured to transition from a closed state to an open state to place the fluid transfer device in the third state.

6 . The system of claim 5 , wherein the flow-based assay device is in fluid communication with the sequestration chamber when the port is in the open state.

7 . The system of claim 1 , wherein the flow-based assay device is one of a sandwich lateral flow assay device or a competitive lateral flow assay device.

8 . The system of claim 1 , wherein the bodily fluid is blood, the target analyte is a biomarker for detecting sepsis in the blood, the biomarker being one of procalcitonin or lactate.

9 . The system of claim 8 , wherein the flow-based assay device includes a conjugate element including a matrix of at least one of enzymes, antibodies, or aptamers.

10 . The system of claim 9 , wherein the matrix includes a combination of chitosan and trehalose configured to stabilize at least a portion of the matrix.

Assignments (2)

Continuity (3)

References Cited (400)